IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-39.   (Cancelled).

Claim 40. (Currently Amended) A pharmaceutical composition useful for treating ~~AIDS, HIV infection or CVI in~~ humans comprising:

- (A)   a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

- (B)   a pharmaceutically acceptable adjuvant or filler.

Claims 41-44.   (Cancelled).

Claim 45. (Currently Amended) A method for enhancing T cell proliferation ~~treating~~ in a subject in need thereof~~afflicted with an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI~~, comprising administering to said subject a pharmaceutical composition comprising:

- (A)   a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is a thio-substituted cAMP analog which is an equatorial diastereomer of 8-substituted 3',5' cyclic adenosine monophosphorothioate (Rp-8-substituted-cAMPS), and wherein said thio-substituted cAMP analog binds to an RIα

- 2 -

subunit of said isozyme and acts as a selective or

specific antagonist of said isozyme; and

(B)   a pharmaceutically acceptable adjuvant or filler.

Claims 46-47.   (Cancelled).

Claim 48. (Previously Amended)   The   method   of   Claim   45,

wherein said cAMP antagonist is selected from the group consisting

of Rp-8-Br-cAMPS,   Rp-8-Br-monobutyryl-cAMPS,   Rp-monobutyryl-cAMPS,

Rp-8-(4-chlorophenyl-thio)-cAMPS,   Rp-piperidino-cAMPS,   and

Rp-8-Cl-cAMPS.

Claim 49. (Previously Presented)   The   method   of   Claim   48,

wherein said cAMP antagonist is selected from the group consisting

of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claims 50-51.   (Cancelled).

- 3 -